|Day Low/High||4.24 / 4.25|
|52 Wk Low/High||3.65 / 13.38|
RPL554 demonstrates a favorable pharmacokinetic and pharmacodynamic profile in cystic fibrosis patients
Accelerates top-line data readouts from ongoing clinical trials with RPL554 in COPD and CF
Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD
Top-line data from the study now expected in mid-2018
Earlier than expected results demonstrate absorption occurs primarily in the lungs following inhaled administration
Dose escalation trial will evaluate RPL554 in approximately 400 COPD patients
Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.